These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 36763879

  • 21. Baricitinib: A Review in Moderate to Severe Atopic Dermatitis.
    Hoy SM.
    Am J Clin Dermatol; 2022 May; 23(3):409-420. PubMed ID: 35503162
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
    Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, de la Peña A, Nunes FP, Janes J, Gamalo M, Donley D, Paik J, DeLozier AM, Nickoloff BJ, Simpson EL.
    J Am Acad Dermatol; 2019 Apr; 80(4):913-921.e9. PubMed ID: 29410014
    [Abstract] [Full Text] [Related]

  • 24. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z, Kosloski MP, Kamal MA, Delevry D, Chuang CC, O'Malley JT, Bansal A.
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [Abstract] [Full Text] [Related]

  • 25. Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study.
    Huang D, Lu J, Tan F.
    Dermatitis; 2024 May; 35(1):77-83. PubMed ID: 37930745
    [Abstract] [Full Text] [Related]

  • 26. Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis.
    Thyssen JP, Bieber T, Kleyn CE, Nosbaum A, Grond S, Petto H, Riedl E, Wollenberg A.
    J Dermatolog Treat; 2023 Dec; 34(1):2216322. PubMed ID: 37345379
    [Abstract] [Full Text] [Related]

  • 27. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial.
    King B, Ko J, Kwon O, Vañó-Galván S, Piraccini BM, Dutronc Y, Yu G, Liu C, Somani N, Ball S, Mesinkovska NA.
    JAMA Dermatol; 2024 Oct 01; 160(10):1075-1081. PubMed ID: 39141364
    [Abstract] [Full Text] [Related]

  • 28. Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.
    Rosmarin D, Fretzin S, Strowd L, Casillas M, DeLozier AM, Dawson Z, Chen S, Lu N, Thyssen JP.
    J Cutan Med Surg; 2022 Oct 01; 26(4):377-385. PubMed ID: 35354410
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan.
    Hagino T, Saeki H, Fujimoto E, Kanda N.
    J Dermatol; 2023 Jul 01; 50(7):869-879. PubMed ID: 36890685
    [Abstract] [Full Text] [Related]

  • 31. Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials.
    Wollenberg A, Kircik L, Simpson E, Brinker D, Katoh N, Rueda MJ, Issa M, Yang F, Feely M, Alexis A.
    Dermatitis; 2023 Jul 01; 34(4):308-314. PubMed ID: 36749121
    [Abstract] [Full Text] [Related]

  • 32. Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults.
    De Greef A, Ghislain PD, de Montjoye L, Baeck M.
    Adv Ther; 2023 May 01; 40(5):2509-2514. PubMed ID: 36944819
    [Abstract] [Full Text] [Related]

  • 33. Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
    Rosmarin D, Casillas M, Chen S, Dawson Z, Pierce E, Zhang H, Bukhalo M, Smith S.
    J Cutan Med Surg; 2022 May 01; 26(3):262-266. PubMed ID: 35086348
    [Abstract] [Full Text] [Related]

  • 34. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores.
    Wollenberg A, Simon D, Kulthanan K, Figueras-Nart I, Misery L, Tangsirisap N, Spina L, Lu N, Grond S, Eyerich K.
    J Eur Acad Dermatol Venereol; 2024 Apr 01; 38(4):695-702. PubMed ID: 38041556
    [Abstract] [Full Text] [Related]

  • 35. Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis.
    Bridgeman SG, Martino AK, Strowd LC.
    Expert Opin Pharmacother; 2023 Apr 01; 24(18):2153-2159. PubMed ID: 38018382
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C, Magnolo N, Maari C, Feeney C, Biswas P, Tatulych S, Valdez H, Rojo R.
    Lancet; 2020 Jul 25; 396(10246):255-266. PubMed ID: 32711801
    [Abstract] [Full Text] [Related]

  • 37. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
    Wan H, Jia H, Xia T, Zhang D.
    Dermatol Ther; 2022 Sep 25; 35(9):e15636. PubMed ID: 35703351
    [Abstract] [Full Text] [Related]

  • 38. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.
    Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A, De Bruin-Weller M, Thaci D, Bissonnette R, Gooderham M, Weisman J, Nunes F, Brinker D, Issa M, Holzwarth K, Gamalo M, Riedl E, Janes J.
    J Eur Acad Dermatol Venereol; 2021 Feb 25; 35(2):476-485. PubMed ID: 32926462
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE).
    Silverberg JI, Bissonnette R, Kircik L, Murrell DF, Selfridge A, Liu K, Ahluwalia G, Guttman-Yassky E.
    J Eur Acad Dermatol Venereol; 2023 Jul 25; 37(7):1366-1374. PubMed ID: 36695074
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
    Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, Zhu L, Papacharalambous J, Vincent MS, Peeva E.
    JAMA Dermatol; 2019 Dec 01; 155(12):1371-1379. PubMed ID: 31577341
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.